Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Bempegaldesleukin · NKTR-214, NKTR-214 PRODRUG

Recombinant protein · Immune activation, directed at IL-2 receptor beta subunit (IL2RB) · developed by Nektar Therapeutics

Phase 1 Most advanced trial (none active)

1 Registered trials

What is Bempegaldesleukin?

Bempegaldesleukin is a recombinant IL-2 conjugated to polyethylene glycol chains that binds IL-2 receptor beta subunit to activate cytotoxic T-lymphocytes and natural killer cells. It is studied in metastatic castration-resistant prostate cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: NKTR-214, NKTR-214 PRODRUG
Drug type: Recombinant protein
Targets: IL-2 receptor beta subunit (IL2RB)
Mechanism: Immune activation, directed at IL-2 receptor beta subunit (IL2RB)
Pathways: T-cell activation, NK cell activation, cytotoxic immune response
Therapy area: Oncology
Developer: Nektar Therapeutics
In trials of: INO
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1
UNII: BNO1JG5MZC

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT03835533	Phase 1	Metastatic Castration-resistant Prostate Cancer	Completed	INO

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Metastatic Castration-resistant Prostate Cancer

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z